Holen Sie sich die Stockscreener-App
36.85
5.02%
1.76
Schlusskurs vom Vortag:
$35.09
Offen:
$36.105
24-Stunden-Volumen:
3.44M
Relative Volume:
1.54
Marktkapitalisierung:
$10.31B
Einnahmen:
$2.08B
Nettoeinkommen (Verlust:
$466.92M
KGV:
23.62
EPS:
1.56
Netto-Cashflow:
$404.94M
1W Leistung:
+5.29%
1M Leistung:
+1.15%
6M Leistung:
+39.95%
1J Leistung:
+77.85%
1-Tages-Spanne:
$35.88
$37.05
1-Wochen-Bereich:
$34.01
$37.05
52-Wochen-Spanne:
$20.14
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.85 | 10.31B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis (EXEL) Stock Jumps Amid New Share Buyback Announcement - GuruFocus.com
Why Exelixis Stock Trounced the Market on Thursday - Nasdaq
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - AOL
Why Exelixis Shares Are Skyrocketing: A Story of Triumph and Strategy - Jomfruland.net
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point - Yahoo Finance
Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio! - Smartkarma
Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours - Marketscreener.com
Exelixis Approves Additional $500 Mln Stock Buyback Program - Nasdaq
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - The Bakersfield Californian
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Nasdaq
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 By Investing.com - Investing.com South Africa
Exelixis director George Poste sells $551,462 in stock By Investing.com - Investing.com Australia
Exelixis director Mary Beckerle sells $425,878 in stock By Investing.com - Investing.com Australia
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock - Investing.com India
Exelixis director Mary Beckerle sells $425,878 in stock - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock By Investing.com - Investing.com Nigeria
Exelixis Executives Sell Shares in February Transactions - TradingView
Exelixis looks to next-gen cancer drug as Cabometyx underwhelms again - PharmaLive
Exelixis's SWOT analysis: cabo patent win boosts stock outlook By Investing.com - Investing.com Nigeria
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? - MSN
Exelixis's SWOT analysis: cabo patent win boosts stock outlook - Investing.com
Exelixis falls after ASCO releases colorectal cancer data - MSN
International Markets and Exelixis (EXEL): A Deep Dive for Investors - Nasdaq
Five-year results see Exelixis’ RCC therapy extending overall survival - Yahoo Finance
Exelixis stock rating cut by Oppenheimer, price target to $33 from $41 - MSN
JMP Securities maintains Exelixis stock with $41 target - MSN
Exelixis Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by StockNews.com - MarketBeat
State of Alaska Department of Revenue Decreases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler Increases Exelixis (NASDAQ:EXEL) Price Target to $38.00 - MarketBeat
Sapient Capital LLC Invests $256,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates - MSN
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX - Business Wire
Exelixis (NASDAQ:EXEL) Given New $29.00 Price Target at Barclays - MarketBeat
Q3 Earnings Forecast for Exelixis Issued By Leerink Partnrs - MarketBeat
Citigroup Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Polaris Capital Management LLC Sells 16,900 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Empowered Funds LLC Takes $7.46 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
EXELExelixis Inc Latest Stock News & Market Updates - StockTitan
Stifel Nicolaus Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Stifel raises Exelixis stock price target to $36, maintains hold - MSN
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Exelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - BioSpace
FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock holds firm with $41 target from JMP Securities - MSN
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress - MSN
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Beckerle Mary C | Director |
Feb 14 '25 |
Sale |
34.88 |
12,210 |
425,878 |
30,406 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Option Exercise |
20.50 |
15,874 |
325,417 |
184,894 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Sale |
34.74 |
15,874 |
551,463 |
169,020 |
| Freire Maria C | Director |
Feb 14 '25 |
Option Exercise |
21.52 |
44,114 |
949,521 |
135,121 |
| Freire Maria C | Director |
Feb 14 '25 |
Sale |
34.94 |
44,114 |
1,541,343 |
91,007 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Option Exercise |
23.24 |
7,712 |
179,227 |
41,974 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Sale |
35.02 |
11,568 |
405,111 |
30,406 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):